Home > Press > Hana Biosciences to Present Data On Marqibo, Its Lead Novel Anti-Cancer Compound, At 2008 American Society of Hematology (ASH) Meeting
![]() |
Abstract:
Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that several presentations related to the Company's lead anti-cancer compound, Marqibo(r) (vincristine sulfate injection, OPTISOME(tm)), will be presented at the upcoming annual meeting of the American Society of Hematology (ASH) in San Francisco during December 6-9, 2008.
The following posters will be presented in Hall A of the Moscone Center at the ASH annual meeting. Text of these abstracts can be viewed on the ASH website at www.hematology.org.
* In Vivo Anti-Tumor Efficacy of Vincristine Sulfate Liposomes
Injection (VSLI, Marqibo) in Multiple Myeloma (abstract #2760;
Sunday, Dec. 7, 6:00 PM)
* Peripheral Neuropathy Profile of Vincristine Sulfate Liposomes
Injection (VSLI, Marqibo), a Nanoparticle Vincristine Formulation,
in Adult Subjects with Relapsed/Refractory Acute Lymphoblastic
Leukemia (ALL) and Non-Hodgkin's Lymphoma (NHL) (abstract #2928;
Monday, Dec. 8, 5:30 PM)
* Phase 1 Study of Weekly Vincristine Sulfate (VCR) Liposomes
Injection (VSLI, Marqibo) Plus Dexamethasone in Adults with Relapsed
or Refractory Acute Lymphoblastic Leukemia (ALL) (abstract #2930;
Monday, Dec. 8, 5:30 PM)
####
About Hana Biosciences
Hana Biosciences, Inc. (Nasdaq:HNAB) is a South San Francisco, CA-based biopharmaceutical company focused on acquiring, developing, and commercializing innovative products to strengthen the foundation of cancer care. The company is committed to creating value by building a best-in-class team, accelerating the development of lead product candidates, expanding its pipeline by being an alliance partner of choice, and nurturing a unique company culture.
For more information, please click here
Contacts:
Hana Biosciences
Investor & Media Contacts:
Investor Relations Team
(650) 588-6641
Invigorate Communications
Gregory Gin
(908) 376-7737
Copyright © GlobeNewswire, Inc.
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
New organic molecule shatters phosphorescence efficiency records and paves way for rare metal-free applications July 5th, 2024
Single atoms show their true color July 5th, 2024
New method cracked for high-capacity, secure quantum communication July 5th, 2024
Searching for dark matter with the coldest quantum detectors in the world July 5th, 2024
Nanomedicine
The mechanism of a novel circular RNA circZFR that promotes colorectal cancer progression July 5th, 2024
Diamond glitter: A play of colors with artificial DNA crystals May 17th, 2024
Advances in priming B cell immunity against HIV pave the way to future HIV vaccines, shows quartet of new studies May 17th, 2024
Announcements
New organic molecule shatters phosphorescence efficiency records and paves way for rare metal-free applications July 5th, 2024
Single atoms show their true color July 5th, 2024
New method cracked for high-capacity, secure quantum communication July 5th, 2024
Searching for dark matter with the coldest quantum detectors in the world July 5th, 2024
Events/Classes
A New Blue: Mysterious origin of the ribbontail ray’s electric blue spots revealed July 5th, 2024
Researchers demonstrate co-propagation of quantum and classical signals: Study shows that quantum encryption can be implemented in existing fiber networks January 20th, 2023
![]() |
||
![]() |
||
The latest news from around the world, FREE | ||
![]() |
![]() |
||
Premium Products | ||
![]() |
||
Only the news you want to read!
Learn More |
||
![]() |
||
Full-service, expert consulting
Learn More |
||
![]() |